Rationale for the clinical use of a ribosome-component immune modulator

Allergy and Asthma Proceedings

Volumn 30, Issue 4 SUPPL. 1, 2009, Pages

  Pregliasco, Fabrizio ^a   Terracciano, Luigi ^b   Marcassa, Sergio ^c   Zava, Dario ^d   Anselmi, Giovanni ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Melloni Hospital   (Italy)

^c Medical Marketing Department   (Italy)

^d Istituto Lusofarmaco d'Italia   (Italy)

Author keywords

Activation; Epitopes; Immune system; Immunogenicity; Immunoglobulin; Klebsiella pneumoniae; Natural cytoxicity; Respiratory recurrent infections; Ribosome component immune modulator

Indexed keywords

BACTERIAL VACCINE; BIOMUNIL; IMMUNOGLOBULIN A; RIBOMUNYL; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; B LYMPHOCYTE; BACTERIAL MEMBRANE; BACTERIOLYSIS; CELL PROLIFERATION; DRUG MECHANISM; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; KLEBSIELLA PNEUMONIAE; MACROPHAGE; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RIBOSOME; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; EPITOPES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; KLEBSIELLA PNEUMONIAE; RESPIRATORY TRACT INFECTIONS; VACCINATION;

EID: 68949091880     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3249     Document Type: Review

References (60)

1. Graham NM. The epidemiology of acute respiratory infections in children and adults: A global perspective. Epidemiol Rev 12:149-1118, 1990.
2. Rovers MM, Balemans WA, Sanders EA, et al. Persistence of upper respiratory tract infections in a cohort followed from childhood to adults. Fam Pract 23:286-290, 2006.
3. Fendrick AM, Saint S, Brook I, et al. Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clin Ther 23:1683-1706, 2001. (Pubitemid 33063593)
4. Centanni S, Pregliasco F, Bonfatti C, et al. Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. J Chemother 9:273-278, 1997. (Pubitemid 27346574)
5. Youmans AS, and Youmans GP. Immunogenic activity of a ribosomal fraction obtained from Mycobacterium tuberculosis. J Bacteriol 89:1291-1298, 1965.
6. Venneman MR, and Bigley NJ. Isolation and partial characterization of an immunogenic moiety obtained from Salmonella typhimurium. J Bacteriol 100:140-148, 1969.
7. Winston S, and Berry LJ. Immunity induced by ribosomal extracts from Staphylococcus aureus. J Reticuloendothel Soc 8:66-73, 1970.
8. Thompson HCW, and Snyder IS. Protection against pneumococcal infection by a ribosomal preparation. Infect Immun 3:16-23, 1971.
9. Schalla WO, and Johnson W. Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes. Infect Immun 11:1195-1202, 1975.
10. Actor P, Pitkin D, Goore MY, et al. Nonspecific protective action against Vibrio cholerae of SK&F 42319, a ribonucleic acid obtained from bacteriophage-infected Escherichia coli. Infect Immun 6:886-888, 1972.
11. Baba T. Immunogenic activity of a ribosomal fraction obtained from Pasteurella multocida. Infect Immun 15:1-6, 1977.
12. Dussourd d'Hinterland L, Michel FB, Normier G, and Pinel AM. Les vaccins ribosomaux. Rev Franç Allergol 17:9-14, 1977.
13. Lieberman MM. Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity. Infect Immun 21:76-86, 1978.
14. Levenson VI, Egorova TP, Belkin ZP, et al. Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine. Infect Immun 59:3610-3618, 1991.
15. Yamada T. Immunological properties of ribosomal proteins from Mycobacterium bovis BCG. Infect Immun 61:4005-4007, 1993.
16. Bellanti JA, Olivieri D, and Serrano E. Ribosomal immunostimulation. Assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in children and adults. BioDrugs 17:355-367, 2003.
17. Robert D, Quillon JP, Ivanoff B, et al. Role of interferon in mice in protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Klebsiella pneumoniae as adjuvant. Infect Immun 26:515-519, 1979.
18. Lafont S, Millet I, Kouassi E, et al. Induction of murine B cell proliferation and immunoglobulin synthesis by some bacterial ribosomes. Microbiol Immunol 32:1043-1058, 1988. (Pubitemid 18274148)
19. Minonzio F, Ongari AM, Venegoni E, et al. Immunomodulation of polymorphonuclear leukocytes by D53 Immucytal and its constitutive fractions. Boll Ist Sieroter Milan 68:241-248, 1989. (Pubitemid 20122711)
20. Hbabi-Haddioui L, and Roques C. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant. Drugs 54:29-32, 1997.
21. Fontanges R, Robert D, Content Y, et al. Pouvoir vaccinant de ribosomes extrait de K. pneumoniae, D. pneumoniae, Streptococcus pyogenes, Haemophilus influenzae et d'une fraction membranaire de K. pneumoniae. Rev Fr Allergol 17:35-81, 1977.
22. Fontanges R, Robert D, Content Y, et al. Study of the immunogenicity of ribosomes and ribosomal RNA extracted from K. pneumoniae and S. pneumoniae. Arzneimittelforsch 30:142-172, 1980.
23. Domzig W, Pinel AM, Normier G, et al. Cross-protection induced by bacterial ribosomes. Maladies Médicaments 3:19-24, 1987.
24. Michel FB, Clavel R, and Coulet P. Double-blind study of the elements of the immune response induced by Rybomunyl tablets administered orally. Evaluation of the results in comparison with other galenic forms. Clinical Study Report, Pierre Fabre Medicament, 1981.
25. o Immunological study. Allergol Immunopathol (Madr) 10:53-60, 1982.
26. Sabbah A. Étude d'un immuno-régulateur dans l'asthme: le Ribomunyl. Allergie Immunol 18:41-43, 1986. (Pubitemid 16159374)
27. Faure GC, Béné MC, Simon C, et al. Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. Int J Immunopharmacol 12:315-320, 1990. (Pubitemid 20111665)
28. Tresca E, Dolce V, De Matthaeis G, et al. Azione del Biomunil sulla risposta immunitaria di tipo umorale. Farmaci e Terapia 8:171-174, 1991.
29. Faure GC, Hauer S, Mole C, et al. Peripheral blood specific antibody-forming cells after oral stimulation with a ribosomal vaccine. Dev Biol Stand 77:175-181, 1992.
30. Béné MC, Kahl L, Perruchet AM, et al. Bacterial lysates and ribosomes as inducers of specific immune responses: A comparative study. Scand J Immunol 38:496-498, 1993. (Pubitemid 23327293)
31. Lusuardi M, Capelli A, Carli S, et al. Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. Chest 103:1783-1791, 1993. (Pubitemid 23174315)
32. Zanin C, Perrin P, Bene MC, et al. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. Int J Immunopharmacol 16:497-505, 1994. (Pubitemid 24193264)
33. Kolopp-Sarda MN, Bene ME, Allaire JM, et al. Kinetics of specific salivary IgA responses in man after oral challenge by ribosomal immunostimulant. Int J Immunopharmacol 19:181-186, 1997.
34. Bene MC, and Faure GC. From Peyer's patches to tonsils. Specific stimulation with ribosomal immunotherapy. Drugs 54:24-28, 1997.
35. Libon C, Haeuw JF, Crouzet F, et al. Streptococcus pneumoniae polysaccharides conjugated to the outer membrane protein A from Klebsiella pneumoniae elicit protective antibodies. Vaccine 20:2174-2180, 2002.
36. Caliot E, Libon C, Kerneis S, et al. Translocation of ribosomal immunostimulant through an in vitro-reconstituted digestive barrier containing M-like cells. Scand J Immunol 52:588-594, 2000. (Pubitemid 32011773)
37. Jeannin P, Magistrelli G, Herbault N, et al. Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs. Eur J Immunol 33:326-333, 2003. (Pubitemid 36267596)
38. Pichavant M, Delneste Y, Jeannin P, et al. Outer membrane protein A from Klebsiella pneumoniae activates bronchial epithelial cells: Implication in neutrophil recruitment. J Immunol 171: 6697-6705, 2003.
39. Jeannin P, Bottazzi B, Sironi M, et al. Complexity and complementary of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 22:551-560, 2005. (Pubitemid 40719191)
40. Jongmans W, Tiemessen DM, Van Vlodrop IJ, et al. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: The importance of maturation cocktails. J Immunother 28:480-487, 2005. (Pubitemid 41232569)
41. Peng JC, Thomas R, and Nielsen LK. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 28:599-609, 2005. (Pubitemid 41533094)
42. Roques C, Frayret MN, Luc J, et al. Effect of an in vivo immunostimulant treatment on PMN functions: Interaction with antibiotics in vitro. Int J Immunopharmacol 13:1051-1057, 1991.
43. Sironi M, Sica A, Riganti F, et al. Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int J Immunopharmacol 12:397-402, 1990. (Pubitemid 20203631)
44. Dussourd d'Hinterland L, Pinel AM, and Rey G. Ribosomal vaccines: Immunological study. Arzneimittelforschung 30:132-141, 1980.
45. Normier G, Pinel AM, D'Hinterland LD, et al. NK-cell stimulating properties of a membrane proteoglycan from non-capsulated Klebsiella pneumoniae biotype A. Acta Pathol Microbiol Immunol Scand [C] 93:233-243, 1985.
46. Michel FB, Dussourd d'Hinterland L, Bousquet J, et al. Immunostimulant by a ribosomal vaccine associated with a bacterial cell-wall adjuvant in humans. Infect Immun 20:760-769, 1978.
47. Ramstadt U. Stimulation of NK cells using Klebsiella pneumoniae membrane proteoglycans. Maladies Médicaments 3:25-36, 1987.
48. Meroni PL, Barcellini W, Borghi MO, et al. In Vitro Effect of Ribommunyl and Its Fractions on Human Mononuclear Cells. Les Congrès Européens d'Oto-Rhino-Laryngologie, Paris 1988, 26-29.
49. Allavena P, Erroi A, Pirelli A, et al. Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes. Int J Immunopharmacol 11:29-34, 1989. (Pubitemid 19019327)
50. Scheffer J, Ounis I, and Konig W. Effect of an immunostimulatory substance of Klebsiella pneumoniae on inflammatory responses of human granulocytes, basophils and platelets. Arzneimittelforsch 41:815-820, 1991.
51. Luini W, De Rossi M, Licciardello L, et al. Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int J Immunopharmacol 13:631-637, 1991.
52. Hbabi L, Roques C, Michel G, et al. In vitro stimulation of polymorphonuclear cell adhesion by ribomunyl and antibiotic + ribomunyl combinations: Effects on CD18, CD35, and CD16 expression. Int J Immunopharmacol 15:163-173, 1993.
53. Sica A, Saccani A, Borsatti A, et al. Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med 185:969-974, 1997. (Pubitemid 27119881)
54. Boccaccio C, Jacod S, Kaiser A, et al. Identification of a clinical-grade maturation factor for dendritic cells. Immunotherapy 25:88-96, 2002. (Pubitemid 34052839)
55. Spisek R, Brazova J, Rozkova D, et al. Maturation of dendritic cells by bacterial immunomodulators. Vaccine 22:2761-2768, 2004. (Pubitemid 38900652)
56. Rahimy MC, Bernaudin F, Doppelt E, et al. Ex vivo study of the effect of ribomunyl on the release of oxygen radicals by polynuclear neutrophils. Allerg Immunol 21:201-203, 1989. (Pubitemid 19164142)
57. Kantar A, Oggiano N, Romagnoni GG, et al. Effect of oral administration of bacterial extracts on the bactericidal capacity of polymorphonuclear leucocytes in children with recurrent respiratory infections. J Int Med Res 19:451-456, 1991.
58. Pujol JL, Klein B, Godard P, et al. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin-1 in vitro. Chest 100:644-648, 1991.
59. Roques C, Frayret MN, Luc J, et al. Immunostimulant effects on granulocyte functions during an acute respiratory infection. Dev Biol Stand 77:183-187, 1992.
60. Moniuszko T, Rutkowski R, and Chyrek-Borowska S. Effect of Ribomunyl therapy on production of selected cytokines by mononuclear peripheral blood cells in nonatopic bronchial asthma. Pneumonol Alergol Pol 63:71-75, 1995.